H.R. 1672 119th Congress
Maintaining Investments in New Innovation Act
Latest action, Feb 27, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
How the House voted
The House hasn't taken a roll call on this bill in the Congresses covered.
51 cosponsors
Sponsored by Donald G. Davis (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
- Democrat
- Republican
- Independent
Referred to: House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
The top 25 of 34 clients, by reports
| Client | Lobbying firm | Reports | Reports totaling | From | To | House |
|---|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | TIBER CREEK GROUP | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| ALNYLAM PHARMACEUTICALS, INC. | LMH STRATEGIC SOLUTIONS | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| ALNYLAM PHARMACEUTICALS, INC. | SPLITOAK STRATEGIES LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| AMGEN INC | 7 | $21.5M | Q1 2025 | Q3 2026 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | $12.1M | Q1 2025 | Q3 2026 | yes | |
| HEALTHCARE INSTITUTE OF NEW JERSEY | 7 | $333K | Q1 2025 | Q3 2026 | yes | |
| IONIS PHARMACEUTICALS, INC. | 7 | $910K | Q1 2025 | Q3 2026 | yes | |
| NOVARTIS | BGR GOVERNMENT AFFAIRS | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| NOVARTIS | CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| NOVARTIS | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| NOVARTIS | 7 | $14.0M | Q1 2025 | Q3 2026 | yes | |
| NOVARTIS, INC. | TODD STRATEGY GROUP | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) | TIBER CREEK GROUP | 7 | $420K | Q1 2025 | Q3 2026 | yes |
| ALNYLAM PHARMACEUTICALS, INC. | TODD STRATEGY GROUP | 6 | $0 | Q1 2025 | Q2 2026 | yes |
| HARMONY BIOSCIENCES | 6 | $1.1M | Q4 2025 | Q3 2026 | yes | |
| IONIS PHARMACEUTICAL, INC. | FORBES-TATE | 6 | $210K | Q4 2025 | Q3 2026 | yes |
| IONIS PHARMACEUTICALS, INC. | LMH STRATEGIC SOLUTIONS | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| NOVARTIS | DLA PIPER LLP (US) | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| NOVARTIS, INC. | FORBES-TATE | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| ASSOCIATION OF BLACK CARDIOLOGISTS | VENABLE LLP | 5 | $150K | Q4 2025 | Q3 2026 | yes |
| PUBLIC CITIZEN | 5 | $449K | Q1 2025 | Q1 2026 | yes | |
| THE ALS ASSOCIATION | 5 | $150K | Q4 2025 | Q3 2026 | yes | |
| THE MENDED HEARTS, INC. | TROUTMAN STRATEGIES | 5 | $255K | Q4 2025 | Q3 2026 | yes |
| GENENTECH USA, INC. | AVENUE SOLUTIONS | 4 | $0 | Q4 2025 | Q3 2026 | yes |
| PERSONALIZED MEDICINE COALITION | 4 | $170K | Q4 2025 | Q1 2026 | yes |